 Connection
Liron Caplan to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications Liron Caplan has written about Tumor Necrosis Factor-alpha.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.542 |
|
|
|
-
Sen R, Caplan L. Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials. Curr Opin Pharmacol. 2022 12; 67:102307.
Score: 0.147
-
Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Joseph GJ, Harrison DJ, Sauer BC. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. Adv Ther. 2016 08; 33(8):1347-59.
Score: 0.095
-
Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smith JA, Borenstein D, Hiratzka J, Weiss PF, Inman RD, Majithia V, Haroon N, Maksymowych WP, Joyce J, Clark BM, Colbert RA, Figgie MP, Hallegua DS, Prete PE, Rosenbaum JT, Stebulis JA, van den Bosch F, Yu DT, Miller AS, Reveille JD, Caplan L. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2016 Feb; 68(2):282-98.
Score: 0.090
-
Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Harrison DJ, Joseph GJ, Sauer BC. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. J Rheumatol. 2014 Oct; 41(10):1935-43.
Score: 0.083
-
Lane MA, McDonald JR, Zeringue AL, Caplan L, Curtis JR, Ranganathan P, Eisen SA. TNF-a antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Baltimore). 2011 Mar; 90(2):139-145.
Score: 0.065
-
McCulley CB, Barton JL, Cannon GW, Sauer BC, Teng CC, George MD, Caplan L, England BR, Mikuls TR, Baker JF. Body mass index and persistence of conventional DMARDs and TNF inhibitors in rheumatoid arthritis. Clin Exp Rheumatol. 2019 May-Jun; 37(3):422-428.
Score: 0.028
-
Baker JF, Sauer BC, Cannon GW, Teng CC, Michaud K, Ibrahim S, Jorgenson E, Davis L, Caplan L, Cannella A, Mikuls TR. Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis. Arthritis Rheumatol. 2016 08; 68(8):1818-27.
Score: 0.024
-
Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006 Feb; 54(2):628-34.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|